Brief: FDA Sets Review Date For Ascelia Pharma's Orviglance NDA For July 3
17/11/2025 06:26
Nov 17 (Reuters) - Ascelia Pharma AB ACELP.ST: SAID ON SATURDAY U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED THE NEW DRUG APPLICATION (NDA) FOR ORVIGLANCE FOR REVIEW FDA HAS SET AN ACTION DATE OF JULY 3, 2026 Source text for Workspace: nMFN6JLPNK Further company coverage: ACELP.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))